Beutel Goodman & Co Ltd. Sells 98,740 Shares of Eupraxia Pharmaceuticals Inc. $EPRX

Beutel Goodman & Co Ltd. decreased its position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) by 2.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,529,124 shares of the company’s stock after selling 98,740 shares during the period. Beutel Goodman & Co Ltd. owned 5.43% of Eupraxia Pharmaceuticals worth $32,289,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of EPRX. Persistent Asset Partners Ltd purchased a new position in Eupraxia Pharmaceuticals during the 2nd quarter worth $25,000. BlackRock Inc. purchased a new stake in Eupraxia Pharmaceuticals in the second quarter valued at about $40,000. China Universal Asset Management Co. Ltd. raised its stake in Eupraxia Pharmaceuticals by 28.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock valued at $133,000 after buying an additional 3,500 shares during the last quarter. AXQ Capital LP raised its stake in Eupraxia Pharmaceuticals by 34.2% in the second quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock valued at $140,000 after buying an additional 5,390 shares during the last quarter. Finally, Cibc World Market Inc. purchased a new stake in Eupraxia Pharmaceuticals in the second quarter valued at about $1,539,000.

Eupraxia Pharmaceuticals Stock Up 7.7%

Eupraxia Pharmaceuticals stock opened at $7.42 on Tuesday. The firm has a market cap of $498.92 million, a price-to-earnings ratio of -7.27 and a beta of 1.04. Eupraxia Pharmaceuticals Inc. has a 52 week low of $5.57 and a 52 week high of $9.32. The business’s 50-day moving average price is $7.56 and its 200 day moving average price is $7.26. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. As a group, sell-side analysts anticipate that Eupraxia Pharmaceuticals Inc. will post -0.90 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Stifel Nicolaus set a $25.00 price target on Eupraxia Pharmaceuticals in a report on Thursday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 8th. Royal Bank Of Canada assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Monday. They set an “outperform” rating and a $14.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, October 20th. Finally, Wedbush initiated coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. They issued an “outperform” rating and a $17.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.17.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.